This inventor holds 1 USPTO granted patent and 1 EPO patent. Top assignee: Universitetet I Oslo. Active years: 2025.
Company Filing History:
Years Active: 2025
Title: Lenka Besse: Innovator in Cancer Treatment
Introduction
Lenka Besse is a prominent inventor based in St. Gallen, Switzerland. She has made significant contributions to the field of cancer treatment, particularly through her innovative research on ALK inhibitors. Her work focuses on addressing ALK-negative cancers and plasma cell-mediated diseases, which are critical areas in oncology.
Latest Patents
Lenka Besse holds 1 patent for her invention titled "ALK inhibitors for treatment of ALK-negative cancer and plasma cell-mediated diseases." This patent presents a method for treating ALK-negative/LTK-positive cancer by administering a pharmaceutically effective dose of a linear inhibitor of ALK. The invention is particularly useful in treating multiple myeloma, including cases that are resistant to proteasome inhibitors.
Career Highlights
Lenka Besse is affiliated with the University of Oslo, where she continues her research and development in cancer therapies. Her academic background and dedication to scientific advancement have positioned her as a key figure in her field.
Collaborations
Lenka collaborates with notable colleagues, including Hesso Farhan and Ludvig Munthe. Their combined expertise enhances the research efforts and contributes to the development of innovative treatments.
Conclusion
Lenka Besse's work in developing ALK inhibitors represents a significant advancement in the treatment of challenging cancers. Her contributions to medical science are invaluable and continue to inspire future innovations in oncology.